SINGLE-CHAIN ZAGOTENEMAB ANTIBODY-TRANSFERRIN FUSION PROTEIN FOR ENHANCED EFFICACY AND INDICATIONS
Application
US20260078173A1
Kind: A1
Mar 19, 2026
Inventors
Matthias Magoola, Sarfaraz K. Niazi
Abstract
The efficacy and indication of zagotenemab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.
CPC Classifications
C07K 16/18
C07K 14/79
C07K 2317/622
C07K 2319/00
Filing Date
2024-09-16
Application No.
18886969